Why it movedWhy Illumina (ILMN) Stock Is Sinking Today
Illumina plunged 19.3% on Friday after third-quarter results that topped profit estimates and raised its 2026 forecast failed to ease worries about slowing growth.
ILMN▼ 19.2%
Consumer and health care
Claire Okafor
Consumer, retail and health care. Claire Okafor is a pen name; every Mostly Markets writer uses one.
Friday, 30 October
Why it moved
EarningsMondelez (MDLZ) Tops Q3 Profit Estimates as Volumes Grow
Mondelez earned an adjusted 78 cents a share, above the 71 cents analysts expected, as more snacks sold lifted organic sales 2.1%. The stock rose 4.1% early Friday.
MDLZ▲ 4.1%
EarningsStryker (SYK) Misses Q3 Estimates as Hip and Knee Procedures Slow
Stryker's revenue rose 7.7% to $6.52 billion, short of the $6.58 billion expected, and it cut its 2026 growth forecast. The stock was down 7.6% Friday morning.
SYK▲ 2.5%
EarningsBristol Myers Squibb (BMY) Tops Q3 Estimates as Eliquis Sales Grow 26%
Bristol Myers Squibb's revenue rose 7% to $13.07 billion, beating the $12.56 billion Zacks consensus, and it raised its 2026 sales forecast. The stock rose 1.4% on Thursday.
BMY▲ 1.4%
EarningsAltria (MO) Tops Q3 Estimates as It Raises 2026 Profit Forecast
Altria's revenue net of excise taxes rose 3.6% to $5.44 billion, ahead of the $5.31 billion expected, and it raised its 2026 forecast. The stock jumped 5.2% on Thursday.
MO▲ 3.3%
EarningsStarbucks (SBUX) Beats Q4 Profit Estimates but Revenue Falls Short
Starbucks earned an adjusted 80 cents a share, above the 72 cents expected, as global comparable sales rose 7.2%, but revenue fell 4% to $9.14 billion. The stock slipped 0.6% on Friday morning.
SBUX▲ 2.2%
Thursday, 29 October
EarningsGilead (GILD) Tops Q3 Estimates as HIV Sales Grow 18%
Gilead's revenue rose 7% to $8.30 billion, beating the $7.81 billion expected, and it raised its 2026 sales forecast. The stock was up 3% after hours.
GILD▲ 4.0%
EarningsMerck (MRK) Tops Q3 Estimates as Keytruda and Gardasil Outperform
Merck's sales rose 5% to $18.09 billion, ahead of the $17.31 billion expected, and it raised its 2026 profit forecast. The stock rose 3.8% on Thursday.
MRK▲ 3.8%
Earnings previewAbbVie (ABBV) Reports Earnings Tomorrow: What to Watch
AbbVie reports before the open on Friday. Analysts expect adjusted EPS of $3.74 to $3.79, within or above the $3.73 to $3.77 the company guided to after an 11-cent charge for acquired research.
ABBV▲ 1.7%
EarningsEli Lilly (LLY) Tops Q3 Estimates as Mounjaro Sales Jump 65%
Lilly's revenue rose 39% to $24.40 billion, beating the $22.61 billion expected, and it raised its 2026 sales forecast by $5.5 billion at the midpoint. The stock jumped 6.6% to a record close.
LLY▲ 6.6%
Why it movedWhy Carvana (CVNA) Stock Is Soaring Today
Carvana soared 15.7% on Thursday after selling a record 217,385 cars in the third quarter, up 39%, with revenue of $8.04 billion ahead of estimates.
CVNA▲ 15.7%
Tuesday, 27 October
Why it movedGeneral Motors (GM) Shares Jump After It Moves Its Listing to the Nasdaq
GM jumped 5.5% on Tuesday, its best day since January, after saying it will move its stock listing from the NYSE to the Nasdaq on 17 November, making it eligible for the Nasdaq-100.
GM▲ 5.5%
EarningsCoca-Cola (KO) Tops Q3 Estimates as Volume Grows Outside North America
Coca-Cola earned 91 cents a share on a comparable basis, beating the 88 cents expected, on revenue up 7% to $13.4 billion, and raised its 2026 profit forecast for a third straight quarter.
KO▼ 1.6%
Monday, 26 October
Why it movedDoorDash (DASH) Shares Slide on Report It Is in Talks to Buy Instacart
DoorDash slid 6.1% on Monday after The Wall Street Journal reported it is in advanced talks to buy delivery rival Instacart, in a deal that a source told Reuters would value Instacart at about $17 billion.
DASH▼ 6.1%
Thursday, 22 October
Why it movedWhy Moderna (MRNA) Stock Is Sinking Today
Moderna plunged 17.6% on Thursday after Phase 3 results for its melanoma vaccine with Merck appeared online two days early, showing a 42% cut in the risk of relapse or death.
MRNA▼ 17.6%
EarningsProcter & Gamble (PG) Tops Fiscal Q1 Estimates as Volumes Grow 2%
P&G earned $2.00 a share on a core basis, above the $1.88 analysts expected, on sales of $23.3 billion, up 4%. It kept its full-year outlook despite a $1.4 billion commodity-cost headwind.
PG▲ 5.6%
